Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook
Eli Lilly reported Q2 revenue of $23.0B, up 48% year over year, and raised full-year revenue guidance to $85B-$87B from $82B-$85B. Mounjaro revenue rose 91% to $9.9B and Zepbound 46% to $4.9B. The company also increased R&D and marketing costs and noted lower realized prices and higher acquisition-related charges.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised full-year revenue and profit outlook, supported by obesity franchise growth, while the main counterweight is realized price declines and higher acquisition and restructuring charges that can pressure reported EPS and margins.
Market read
A guidance raise tied to obesity demand is a direct catalyst for positioning, but the disclosed realized price declines and deal-related charges raise near-term earnings-quality and margin uncertainty.
What to watch
Investors may underweight the magnitude of acquired R&D charges ($2.8B) and impairment/restructuring ($703M) when extrapolating clean EPS growth from non-GAAP results.
Background
The article summarizes Lilly’s Q2 performance, product-level growth in Mounjaro and Zepbound, and management’s updated full-year targets, alongside pricing and acquisition-related cost pressures.
Ticker impact
Eli Lilly reported Q2 revenue up 48% and raised full-year revenue guidance to $85B-$87B, citing obesity franchise momentum.
Bullish bias for the next few sessions, with volatility risk as investors weigh guidance against falling realized prices and higher acquisition-related charges.
The article provides concrete, time-sensitive fundamentals: Q2 revenue and product growth, explicit full-year guidance range, and quantified headwinds (realized price down 13%, international down 36%, higher acquired R&D and impairment/restructuring).
Market effects
Reinforces GLP-1/obesity demand strength while highlighting pricing pressure from reimbursement expansion, which can affect sentiment across large pharma obesity peers.
International pricing weakness tied to China reimbursement list inclusion may keep focus on China policy and payer dynamics for obesity drugs.
Guidance and obesity franchise growth can influence global biotech/pharma risk appetite and positioning in obesity-related supply chains and pipeline expectations.
Counterpoint
The guidance raise may be partially offset by worsening realized pricing and rising deal-related charges, implying earnings quality could deteriorate even if top-line growth stays strong.
Key entities
- companyEli Lilly
Reported Q2 results with strong obesity franchise growth and raised full-year guidance; also disclosed pricing declines and higher acquisition-related charges.
- productMounjaro
Q2 revenue jumped 91% to $9.9B, driving much of the obesity franchise momentum.
- productZepbound
Q2 revenue climbed 46% to $4.9B, contributing to franchise growth.
- pipeline_assetretatrutide
Three Phase 3 trials read out positively, supporting a planned obesity application submission in Q1 2027.
